Avaleht4DX • ASX
add
4DMedical Ltd
Viimane sulgemishind
0,56 $
Tänane vahemik
0,59 $ - 0,63 $
Aasta vahemik
0,41 $ - 0,83 $
Turuväärtus
250,69 mln AUD
Keskmine maht
904,84 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
ASX
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(AUD) | juuni 2024info | Y/Y muutus |
---|---|---|
Käive | 1,48 mln | 1 172,70% |
Põhitegevusega seonduv kulu | 12,56 mln | 11,42% |
Puhastulu | −10,19 mln | −33,78% |
Puhaskasumimarginaal | −687,84 | 89,49% |
Puhaskasum aktsia kohta | — | — |
EBITDA | −11,09 mln | −5,51% |
Tõhus maksumäär | −0,01% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(AUD) | juuni 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 30,61 mln | −56,01% |
Kogu vara | 120,02 mln | 29,16% |
Kõik kohustused | 49,09 mln | 128,71% |
Kogu omakapital | 70,93 mln | — |
Emiteeritud aktsiate arv | 410,53 mln | — |
Hinna ja väärtuse suhe P/B | 3,32 | — |
Varade tasuvus | −23,28% | — |
Kapitali tasuvus | −36,73% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(AUD) | juuni 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −10,19 mln | −33,78% |
Põhitegevuse rahakäive | −8,06 mln | 8,54% |
Investeeringute raha | −339,48 tuh | −21,29% |
Finantseerimise raha | −233,98 tuh | −101,11% |
Raha ja raha ekvivalentide muutus | −8,64 mln | −172,48% |
Tasuta rahavoog | −5,43 mln | 13,25% |
Teave
4DMedical is a medical technology company, based in Australia and the United States.
4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report.
4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Tegevjuht
Asutatud
2013
Veebisait
Töötajate arv
145